Related to Flush with Cash, Versartis and Diartis Focus on Drugs Based on Amunix’ XTEN Technology

• Amylin Obtains Temporary Restraining Order Against Eli Lilly
  
• AFFiRiS Invests in Public-Funded Lab to Develop Vaccine Against Diabetes and Cardiometabolic Diseases
  
• Oxford Medical Diagnostics Obtains $1.61M Financing
  
• Court Vacates Temporary Restraining Order Against Lilly in Case Filed by Amylin
  
• Mice Studies Provide Insights on Contradictory Role of Insulin-Degrading Enzyme
  
• Quintiles Invests in Kareus for Phase I Trials of Alzheimer and Type 2 Diabetes Treatments
  
• Collaboration Gives Boehringer Ingelheim Rights to Zealand’s Type 2 Diabetes Candidate
  
• EC Approves Lilly, Amylin, and Alkermes’ Once-Weekly Type 2 Diabetes Drug Bydureon
  
• Promising Data for Type 1 and 2 Diabetes Candidates Presented at ADA Meeting
  
• Astellas Sells Prosidion Subsidiary’s DPP-IV Inhibitor Diabetes Assets to Royalty Pharma for $609M
  
• Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes
  
• EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
  
• Axxam and Polyphor Receive €3.1M for GLP-1 Receptor Diabetes Program
  
• Intercept Signs Potentially $163M Diabetes Drug Development Deal with Servier
  
• Scientists Find High-Fat Diet Causes Beta Cell Dysfunction Leading to Type 2 Diabetes
  
• Santarus and Depomed Amend U.S. Commercialization Arrangement for Type 2 Diabetes Drug
  
• BI and Lilly’s Linagliptin Now Approved to Treat Type 2 Diabetes in Europe
  
• Aeterna Zentaris Reports Positive Phase III Results for AGHD Test
  
• Phase IIIb Study Shows Benefits of Combining Onglyza with Insulin for Type 2 Diabetes
  
• BMS Nabs Global Rights to Ambrx' Fibroblast Growth Factor and Relaxin Candidates for $24M